Novartis Stock: price and insider trades · India
Novartis: what insiders have been doing
Novartis is a listed company. Filings by its managers are published through SEBI (PIT + SAST). 3 insiders have disclosed 3 filings since 10 November 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
With 3 filings in twelve months, the company is quieter than the median of 4 filings across the 1,984 companies we follow on the same exchange.
Insider buying of Novartis has been absent for the past year. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. The shorter that gap, the sooner other investors can see what insiders have done.
Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 17,450,680 shares-Off MarketSEBI:c3b58fcfeb40b5d2e656fbf4ba099c5321f9e1c6
- 17,450,680 shares-Off MarketSEBI:d7b496067b1c2cd4d50bf36e7a5028462d0f24af
- 17,450,680 shares@ ₹789.0028.31% mcap100.0% of flowEquityOff MarketSEBI:b3a3fcd8a9ea2ee0236962182cc043ba4978b557
3 of 3 declarations
About Novartis
Novartis is a global pharmaceutical company based in Switzerland, focused on the research and development of innovative medicines. It primarily operates in the fields of oncology, neuroscience, and cardiovascular diseases.